These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 1612895)

  • 41. Serologic response to measles-mumps-rubella vaccine among children with upper respiratory tract infection.
    Cilla G; Peña B; Marimón JM; Pérez-Trallero E
    Vaccine; 1996 Apr; 14(6):492-4. PubMed ID: 8782345
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Immunity against measles and rubella in Massachusetts schoolchildren.
    Orenstein WA; Herrmann K; Albrecht P; Bernier R; Holmgreen P; Bart KJ; Hinman AR
    Dev Biol Stand; 1986; 65():75-83. PubMed ID: 3556779
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [The immunological efficacy of the combined vaccine Trimovax intended for the prevention of measles, mumps and rubella].
    Samoĭlovich EO; Kapustik LA; Fel'dman EV; Ermolovich MA; Svirchevskaia EIu; Titov LP; Zakharenko DF; Belova EIu; Chernovetskiĭ MA; Korostik TS
    Zh Mikrobiol Epidemiol Immunobiol; 1998; (4):36-40. PubMed ID: 9783398
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Comparison of vaccination with measles-mumps-rubella vaccine at 9, 12, and 15 months of age.
    Redd SC; King GE; Heath JL; Forghani B; Bellini WJ; Markowitz LE
    J Infect Dis; 2004 May; 189 Suppl 1():S116-22. PubMed ID: 15106100
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Measles-mumps-rubella revaccination; 18 months vs. 4-6 years of age: potential impacts of schedule changes.
    Saffar MJ; Fathpour GR; Parsaei MR; Ajami A; Khalilian AR; Shojaei J; Saffar H
    J Trop Pediatr; 2011 Oct; 57(5):347-51. PubMed ID: 21078605
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Gender differences in the reactogenicity of measles-mumps-rubella vaccine.
    Shohat T; Green MS; Nakar O; Ballin A; Duvdevani P; Cohen A; Shohat M
    Isr Med Assoc J; 2000 Mar; 2(3):192-5. PubMed ID: 10774264
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Mumps epidemic in vaccinated children in West Switzerland].
    Ströhle A; Eggenberger K; Steiner CA; Matter L; Germann D
    Schweiz Med Wochenschr; 1997 Jun; 127(26):1124-33. PubMed ID: 9312835
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Immunogenicity and safety of a second dose of measles-mumps-rubella-varicella vaccine in healthy children aged 5 to 6 years.
    Vesikari T; Baer M; Willems P
    Pediatr Infect Dis J; 2007 Feb; 26(2):153-8. PubMed ID: 17259879
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Follow-up surveillance for antibody in human subjects following live attenuated measles, mumps, and rubella virus vaccines.
    Weibel RE; Buynak EB; McLean AA; Hilleman MR
    Proc Soc Exp Biol Med; 1979 Nov; 162(2):328-32. PubMed ID: 515009
    [No Abstract]   [Full Text] [Related]  

  • 50. Immune response to Edmonston-Zagreb measles virus strain in monovalent and combined MMR vaccine.
    Beck M; Smerdel S; Dedić I; Delimar N; Rajninger-Miholic M; Juzbasić M; Manhalter T; Vlatković R; Borcić B; Mihajić Z
    Dev Biol Stand; 1986; 65():95-100. PubMed ID: 3556780
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Comparative study and evaluation of further attenuated, live measles vaccines alone and in combination with mumps and rubella vaccines.
    Wegmann A; Glück R; Just M; Mischler R; Paroz P; Germanier R
    Dev Biol Stand; 1986; 65():69-74. PubMed ID: 3556778
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Responses to triple viral and tetanus vaccination in HIV-infected children].
    Echeverría Lecuona J; Aldamiz-Echevarría Azuara L; Cilla Eguiluz G; Pérez Trallero E
    An Esp Pediatr; 1996 Apr; 44(4):317-20. PubMed ID: 8849078
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [The clinico-immunological evaluation of a bivalent vaccine against measles and rubella].
    Schettini F; Manzionna MM; De Mattia D; Amendola F; Di Bitonto G
    Minerva Pediatr; 1990 Dec; 42(12):531-6. PubMed ID: 2087226
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Age-stratified seroprevalence of measles, mumps and rubella (MMR) virus infections in Switzerland after the introduction of MMR mass vaccination.
    Matter L; Germann D; Bally F; Schopfer K
    Eur J Epidemiol; 1997 Jan; 13(1):61-6. PubMed ID: 9062781
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Duration of immunity and occurrence of secondary vaccine failure following vaccination against measles, mumps and rubella].
    Trier H; Rønne T
    Ugeskr Laeger; 1992 Jul; 154(29):2008-13. PubMed ID: 1509566
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Measles and rubella antibody response after measles-mumps-rubella vaccination in children with afebrile upper respiratory tract infection.
    Ratnam S; West R; Gadag V
    J Pediatr; 1995 Sep; 127(3):432-4. PubMed ID: 7658276
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Evaluation of a two-dose measles, mumps, and rubella vaccination schedule in a cohort of college athletes.
    Coté TR; Sivertson D; Horan JM; Lindegren ML; Dwyer DM
    Public Health Rep; 1993; 108(4):431-5. PubMed ID: 8341775
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Seroconversion and reaction of vaccines, rubella--mumps and measles--rubella--mumps combined.
    Khanjanasthiti P; Jayavasu J; Kashemsant C; Dhanamitta S; Prapattong S
    J Med Assoc Thai; 1978 Sep; 61(9):536-43. PubMed ID: 690542
    [No Abstract]   [Full Text] [Related]  

  • 59. Waning antibody levels and avidity: implications for MMR vaccine-induced protection.
    Kontio M; Jokinen S; Paunio M; Peltola H; Davidkin I
    J Infect Dis; 2012 Nov; 206(10):1542-8. PubMed ID: 22966129
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Decreased measles antibody response after measles-mumps-rubella vaccine in infants with colds.
    Krober MS; Stracener CE; Bass JW
    JAMA; 1991 Apr; 265(16):2095-6. PubMed ID: 2013930
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.